The discovery adds tangible evidence to the investment case for AI in life sciences, a theme that has leaned heavily on promise rather than results. Any read-across is likely to be thematic rather than company-specific, given Anthropic is privately held and ART's commercial value remains unproven.
The discovery adds tangible evidence to the investment case for AI in life sciences, a theme that has leaned heavily on promise rather than results.
Any read-across is likely to be thematic rather than company-specific, given Anthropic is privately held and ART's commercial value remains unproven.
Coming after an AI agent security breach made headlines, the story also offers a counterweight in the wider debate over AI agents operating at scale.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The discovery adds tangible evidence to the investment case for AI in life sciences, a theme that has leaned heavily on promise rather than results. Any read-across is likely to be thematic rather than company-specific, given Anthropic is privately held and ART's commercial value remains unproven. Coming after an AI agent security breach made headlines, the story also offers a counterweight in the wider debate over AI agents operating at scale.
Open the app view to save this story, compare related coverage, and continue from the same source.